PROFECTUS BIOSCIENCES, INC.

Basic Information

6411 Beckley St
BALTIMORE, MD, 21224-6538

Company Profile

n/a

Additional Details

Field Value
DUNS: 185576639
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

    Amount: $238,756.00

    DESCRIPTION: There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activit ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine

    Amount: $3,299,996.00

    DESCRIPTION: The HIV pandemic is one of the greatest public health challenges in history. It is estimated that 33 million people are living with HIV and 2.7 million of those are newly infected In a nu ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    Amount: $2,300,000.00

    DESCRIPTION: Based on the prevailing evidence, we believe that a highly effective vaccine for HIV prophylaxis must induce long-lasting, broadly cross-reactive antibody responses to envelope that exhib ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Optimization of a DNA Subunit Regimen for an HIV Vaccine

    Amount: $2,700,192.00

    DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists o ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. Prime/Boost Vaccine to Prevent Hepatocellular Carcinoma

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): This SBIR application proposes to pre-clinically evaluate a pDNA prime - rVSV boost HCV vaccine intended to improve the sustained virologic response (SVR) rate in ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Optimization of a DNA Subunit Regimen for an HIV Vaccine

    Amount: $224,027.00

    DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists o ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Preclinical Development of Full Length Single Chain

    Amount: $1,990,562.00

    DESCRIPTION (provided by applicant): The positive outcome of the RV144 Phase III vaccine trial (the Thai trial ) that tested an ALVAC-HIV/AIDSVAX B/E prime/boost protocol has prompted the field to re ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Preclinical Development of Full Length Single Chain

    Amount: $299,258.00

    DESCRIPTION (provided by applicant): The positive outcome of the RV144 Phase III vaccine trial (the Thai trial ) that tested an ALVAC-HIV/AIDSVAX B/E prime/boost protocol has prompted the field to re ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants

    Amount: $2,447,584.00

    DESCRIPTION (provided by applicant): Cholera toxin (CT) and the related heat-labile enterotoxin (LT) are AB toxins with cell targeting B domains and enzymatically active A domains. The enzymatically a ...

    SBIR Phase II 2010 Department of Health and Human Services
  10. Novel immune stimulating adjuvants for an HIV DNA Vaccine

    Amount: $283,473.00

    DESCRIPTION (provided by applicant): This document contains proprietary information that Profectus BioSciences requests not be released to persons outside the Government, except for purposes of review ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government